KEY DETAILS
If you've already lost weight on semaglutide or tirzepatide, a monthly shot could someday replace your weekly dose.
For people with obesity, this study aims to clarify how high-dose semaglutide slows stomach emptying, a common concern.
Families of children aged 12 to 17 with obesity from a childhood brain tumor may soon have a tested treatment option.
If you have obstructive sleep apnea, this trial will test whether a weekly tirzepatide shot can replace your CPAP mask.
If semaglutide causes stomach problems for you, completed research on probiotics may soon offer a way to ease them.
On Wednesday, September 30, 2026, GLP-1 Laws tracked five new research developments, all moving through the FDA trial pipeline. Each one asks a sharper question than earlier obesity drug trials did, testing these medications against existing treatments and side effects rather than against a placebo. For patients managing weight loss, sleep apnea, stomach side effects, or a rare form of childhood obesity, these trials could shape what treatment looks like in the years ahead.
Pfizer's new trial focuses on people who already have experience with semaglutide or tirzepatide and have lost weight on one of those drugs. The question is whether a monthly injection of berobenatide (PF-08653944) can maintain that weight loss as well as continuing on a weekly shot. For someone managing a weekly injection schedule, a monthly option could mean fewer trips to the pharmacy and less to remember each week. The trial has not yet started recruiting, so results are likely years away, but it signals that drug makers are thinking beyond the current dosing schedule.
Novo Nordisk is recruiting 60 participants with obesity to look specifically at how a high dose of semaglutide affects the rate at which food leaves the stomach. Slowed stomach emptying is part of how GLP-1 drugs reduce appetite, but it is also tied to side effects like nausea and bloating that many patients report. Understanding this mechanism at higher doses may help doctors set expectations for patients starting or increasing semaglutide treatment. The study is in an early phase and has not yet begun recruiting.
The SEMAFORCRANIO trial will test semaglutide specifically in children and teenagers aged 12 to 17 who developed obesity after treatment for craniopharyngioma, a rare brain tumor. This form of obesity, known as hypothalamic obesity, is different from more common forms because it stems from damage to the part of the brain that regulates hunger and metabolism. Families dealing with this condition have had few treatment options tested in a controlled trial, so a randomized, double-blind study focused on this age group and cause fills a real gap. The trial opens this fall and will compare semaglutide against a placebo across multiple centers.
The trial comparing tirzepatide to positive airway pressure therapy will enroll patients with obstructive sleep apnea and follow them through a randomized, controlled design starting in October 2026. CPAP has long been the standard treatment for sleep apnea, but many patients struggle to use the mask consistently every night. If tirzepatide proves as effective or more effective at reducing apnea episodes, it could give patients and doctors a new option that does not depend on wearing a machine during sleep. The trial is currently listed as not yet recruiting, so patients interested in participating should watch for updates on enrollment.
The completed probiotics trial looked at whether adding probiotics to a GLP-1 treatment plan could reduce the gastrointestinal side effects that lead some patients to lower their dose or stop the medication altogether. Stomach problems such as nausea, constipation, and bloating are among the most commonly reported reasons patients discontinue semaglutide. Because this trial has already finished, results should be available soon, which is sooner than the other trials in this batch. Patients currently managing these side effects may want to watch for the published findings before making changes to their own routine.
None of these trials have produced results yet, and most have not started recruiting. Patients and families affected by these conditions, from sleep apnea to rare childhood obesity, should talk with their doctors about whether a trial might fit their situation, and should keep expectations modest until real data arrives. Two things are worth remembering as this research moves forward. First, comparing these drugs to established treatments like CPAP is a sign that GLP-1 medications are being taken seriously as alternatives, not just as weight-loss aids. Second, side effect research, like the probiotics trial, matters just as much as headline results, because it shapes whether patients can stay on treatment long enough to benefit from it.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.